Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
122.85
+1.78 (1.47%)
May 21, 2024, 4:00 PM EDT - Market closed

Ascendis Pharma Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2012
Revenue
266.7251.177.786.9513.38
Upgrade
Revenue Growth (YoY)
421.20%557.93%11.87%-48.01%26.41%
Upgrade
Cost of Revenue
44.412.143.5200
Upgrade
Gross Profit
222.3239.044.266.9513.38
Upgrade
Selling, General & Admin
264.41221.23160.1876.6748.47
Upgrade
Research & Development
413.45379.62295.87260.9191.62
Upgrade
Operating Expenses
677.86600.85456.05337.57240.09
Upgrade
Operating Income
-455.54-561.81-451.79-330.62-226.72
Upgrade
Interest Expense / Income
44.0750.493.9180.841.22
Upgrade
Other Expense / Income
-25.46-34.48-71.767.71-9.69
Upgrade
Pretax Income
-474.14-577.82-383.94-419.17-218.25
Upgrade
Income Tax
7.35.38-0.37-0.22-0.23
Upgrade
Net Income
-481.45-583.19-383.58-418.96-218.02
Upgrade
Shares Outstanding (Basic)
5656555147
Upgrade
Shares Outstanding (Diluted)
5656555147
Upgrade
Shares Change
0.38%2.37%8.21%8.84%13.20%
Upgrade
EPS (Basic)
-8.55-10.40-7.00-8.28-4.69
Upgrade
EPS (Diluted)
-8.55-10.40-7.00-8.28-4.69
Upgrade
Free Cash Flow
-469.75-500.65-441.88-288.05-181.1
Upgrade
Free Cash Flow Per Share
-8.35-8.93-8.07-5.69-3.89
Upgrade
Gross Margin
83.36%76.28%54.71%100.00%100.00%
Upgrade
Operating Margin
-170.79%-1097.85%-5808.59%-4755.07%-1695.10%
Upgrade
Profit Margin
-180.51%-1139.63%-4931.56%-6025.53%-1630.03%
Upgrade
Free Cash Flow Margin
-176.12%-978.33%-5681.19%-4142.76%-1353.98%
Upgrade
EBITDA
-411.17-509.37-364.64-328.88-210.34
Upgrade
EBITDA Margin
-154.16%-995.37%-4688.12%-4730.10%-1572.64%
Upgrade
Depreciation & Amortization
18.9117.9615.399.456.69
Upgrade
EBIT
-430.08-527.33-380.03-338.33-217.03
Upgrade
EBIT Margin
-161.25%-1030.46%-4886.00%-4865.99%-1622.65%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).